| 2004N-0181 - Critical Path Initiative; Establishment of Docket | |||||||||||||||||||||||
| FDA Comment Number : | EC25 | ||||||||||||||||||||||
| Submitter : | Ms. Susan Krivacic | Date & Time: | 08/02/2004 07:08:41 | ||||||||||||||||||||
| Organization : | PBG Consulting | ||||||||||||||||||||||
| Private Industry | |||||||||||||||||||||||
| Category : | |||||||||||||||||||||||
| Issue Areas/Comments | |||||||||||||||||||||||
| Comment Issues | |||||||||||||||||||||||
| 1. Hurdle Identification. Please describe the product development issue, the nature of the evaluation tool that is out-of-date or absent, how this problem hinders product development, and how a solution would improve the product development process. | |||||||||||||||||||||||
|
| |||||||||||||||||||||||
|
| ||
|
| ||
|
| ||
|
| ||
|
| ||
|
| ||
|
| ||